Anti-IgE therapy results in decreased myeloid dendritic cells in asthmatic airways.
Chand
Hitendra S
HS
Schuyler
Mark
M
Joste
Nancy
N
Hensler
Charlene
C
Tesfaigzi
Yohannes
Y
Masten
Barbara
B
Schrader
Ron
R
Lipscomb
Mary F
MF
D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D001980:Bronchi / Q000166:cytology / Q000276:immunology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D022423:Myeloid Cells / Q000166:cytology / Q000276:immunology; D000069444:Omalizumab; D016896:Treatment Outcome
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C026408:anti-IgE antibodies; D000069444:Omalizumab